Dyne therapeutics news
WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving … WebJan 18, 2024 · Dyne received a clinical hold letter from the FDA on Friday, January 14, 2024 requesting additional clinical and non-clinical information for DYNE-251. The Company expects to submit to the FDA its ...
Dyne therapeutics news
Did you know?
WebApr 11, 2024 · Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company’s stock in a transaction dated Wednesday, … WebDyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like ...
WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on … WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT evaluated monthly repeat doses of DYNE-101 ...
WebGet the latest Dyne Therapeutics Inc (DYN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment … WebMar 23, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to …
WebView the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ.
WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1). reach formaldehidoWebApr 10, 2024 · 5 brokerages have issued twelve-month target prices for Dyne Therapeutics' shares. Their DYN share price forecasts range from $18.00 to $34.00. On average, they … reach forklift truck trainingWebApr 11, 2024 · On average, analysts predict that Dyne Therapeutics will post -3.23 EPS for the current year. Insider Activity at Dyne Therapeutics. In related news, insider Jonathan Mcneill sold 10,000 shares of the company's stock in a transaction dated Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of … reach forklift truckWebApr 4, 2024 · Dyne Therapeutics Stock Performance. Shares of DYN stock opened at $11.05 on Tuesday. The firm’s 50-day moving average is $13.08 and its 200-day moving average is $12.22. The stock has a market ... reach forklifts for rentWebOct 31, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to … reach formula marketingWebSep 13, 2024 · Summary. Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various muscle diseases. DYN has yet to enter Phase 1 safety trials, so the ... reach forklift rental ratesWebMar 2, 2024 · Fourth Quarter and Full Year 2024 Financial Results. Cash position: Cash, cash equivalents and marketable securities were $256.0 million as of December 31, … reach formation